Memantine Hydrochloride Tablet
Product Images NDC 63629-2514

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 63629-2514). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure of Memantine Hydrochloride, showing its molecular framework with amine and hydrochloride components, as well as two methyl groups attached to the structure.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph showing mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo. The y-axis indicates mean change with clinical improvement and decline markers, and the x-axis represents weeks of treatment. Data points with error bars are shown for both groups.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage curve chart showing patients' ADCS-ADL change from baseline comparing placebo and Memantine Hydrochloride (M.HCl). The x-axis represents ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. Two lines depict patient response distributions for placebo and Memantine Hydrochloride groups.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph depicting mean change from baseline in SIB (Severe Impairment Battery) scores over 28 weeks of treatment. Two groups are shown: Placebo (black squares) and Memantine Hydrochloride (M.HCl, open circles). The vertical axis represents mean change with standard error, and the horizontal axis shows weeks of treatment. A dashed line marks clinical improvement at zero change, with clinical decline noted below. Memantine Hydrochloride group shows less decline over time compared to placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A line graph comparing cumulative percentage of patients versus SIB change from baseline. Two data series are shown: one for Placebo (black squares) and one for Memantine Hydrochloride (M. HCl) (white circles). The graph plots patient response over a range of SIB change values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph showing mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. It compares two groups: Placebo/Donepezil (black squares) and Memantine Hydrochloride (M.HCl)/Donepezil (open circles). The y-axis ranges from clinical improvement to clinical decline, illustrating treatment effects over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage plot depicting the percentage of patients against ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) change from baseline. The graph compares two treatments: Placebo/Donepezil and Memantine Hydrochloride (M. HCl)/Donepezil, with Placebo/Donepezil represented by filled squares and M. HCl/Donepezil by open circles.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph showing the mean change from baseline in SIB score over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride (M.HCl)/Donepezil (open circles). The graph indicates clinical improvement above the zero baseline and clinical decline below, with the M.HCl/Donepezil group showing higher improvement scores across most of the treatment period.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage of patients chart depicting SIB (Severe Impairment Battery) change from baseline. It compares two groups using different line markers: Placebo/Donepezil with square markers and Memantine Hydrochloride/Donepezil with circular markers, showing patient response over a range of SIB score changes.*

FDA Label Image

Label (Lbl636292514)

Memantine Hydrochloride Tablets USP 5 mg oral dosage form label from Bryant Ranch Prepack. The label states 5 mg strength and package count of 60 tablets. It includes the NDC 63629-2514-1, barcode, and storage instructions to keep at controlled room temperature. The label also notes 'Rx only' and dispensing in a tight container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.